Premium
Experience of the curie institute in treatment of cancer of the mobile tongue. I. Treatment policies and result
Author(s) -
Decroix Yves,
Ghossein Nemetallah A.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810201)47:3<496::aid-cncr2820470312>3.0.co;2-q
Subject(s) - medicine , tongue , radiation therapy , surgery , cancer , lesion , primary treatment , pathology
Six‐hundred‐two patients were treated for cancer of the mobile tongue between 1959 and 1972. Sixteen percent had T 1 , 48% T 2 , and 36% T 3 lesions. Sixty‐four percent had no palpable nodes (N 0 ). The primary was treated in the majority of patients by radium implant alone or in association with external radiotherapy. Nodes were treated primarily by surgery. Absolute and determinate survivals at five years are 36% and 48%. Determinate survivals for T 1 , T 2 and T 3 tumors are 80%, 56%, and 25%. Fifty‐nine percent of those with clinically negative neck nodes survived five years. Recurrence at the primary site alone or associated with neck failure is 14% for TI, 22% for T 2 and 29% for T 3 . Seventy percent of recurrences occurred within one year. Although 13% of patients who had recurrences at the primary site were alive at five years, 33% of those who had salvage surgery were rescued. Two percent of patients required surgery for radiation necrosis. In our opinion, radiotherapy remains the treatment of choice for the management of the primary lesion of cancer of the mobile tongue.